


Biotinylated Recombinant Human IL-13 Rα1 Fc Chimera Avi-tag

Catalog Number: AVI10436


DESCRIPTION				
Source	Chinese Hamster Ovary cell line, CHO-derived human IL-13 R alpha 1 protein			
	Human IL-13 Rα1 (Ala27-Thr343) Accession # AAB37127.1	IEGRMD	Human IgG ₁ (Pro100-Lys330)	Avi-tag
	N-terminus C-termin			
N-terminal Sequence Analysis	Ala27			
Structure / Form	Biotinylated via Avi-tag			
Predicted Molecular Mass	65 kDa			

SPECIFICATIONS		
SDS-PAGE	93-103 kDa, under reducing conditions	
Activity	Measured by its binding ability in a functional ELISA. When Biotinylated Recombinant Human IL-13 Rα1 Fc Chimera Avi-tag (Catalog # AVI10436) is immobilized at 1 μg/mL (100 μL/well), Recombinant Human IL-13 (Catalog # 213-ILB) binds with an ED ₅₀ of 10-80 ng/mL.	
Endotoxin Level	<0.10 EU per 1 μ g of the protein by the LAL method.	
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.	
Formulation	Supplied as a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.	

PREPARATION AND STORAGE		
Shipping	The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	torage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.	
	 6 months from date of receipt, -20 to -70 °C as supplied. 	
	 1 month, 2 to 8 °C under sterile conditions after opening. 	
	 3 months, -20 to -70 °C under sterile conditions after opening. 	



ecombinant c Chimera VVI10436) is



 $\begin{array}{l} 2 \ \mu g/lane \ of \ Biotinylated \ Recombinant \ Human \\ IL-13 \ R\alpha1 \ Fc \ Chimera \ Avi-tag \ (Catalog \ \# \\ AVI10436) \ was resolved \ with \ SDS-PAGE \\ under \ reducing \ (R) \ and \ non-reducing \ (NR) \\ conditions \ and \ visualized \ by \ Coomassie® \\ Blue \ staining, \ showing \ bands \ at \ 93-103 \ kDa \\ and \ 186-206 \ kDa, \ respectively. \end{array}$

Rev. 10/27/2020 Page 1 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449



Biotinylated Recombinant Human IL-13 Rα1 Fc Chimera Avi-tag

Catalog Number: AVI10436

BACKGROUND

IL-13 RA1, also known as IL-13R and IL-13 RA, is a type I transmembrane protein. Its cDNA encodes a 427 aa precursor protein, with 322 aa extracellular domain, 24 aa transmembrane domain and 60 aa intracellular domain. Within the extracellular domain, human IL-13 RA1 shares 75% and 74% homology with mouse and rat IL-13 RA1, respectively. IL-13 RA1 expresses ubiquitously in all tissues with the highest level in heart, liver, skeletal muscle and ovary (1). As a receptor, IL-13 RA1 can function alone or as a heterodimer with IL-4R. Although both IL-4 and IL-13 signal through IL-4R/IL-13 RA1 heterodimer, there are distinct differences. IL-4 binds IL-4R with high affinity then binds IL-13 RA1 with low affinity. In contrast, IL-13 binds IL-13 RA1 with decent affinity, then binds IL-4R with high affinity (2). In addition, the N-terminal Fibronectin type III domain (D1) of IL-13 RA1 is only required for the binding of IL-13 not IL-4 (3,4). After binding to IL-4 or IL-13, the Tyr residues in the cytoplasmic domain of IL-13 RA1 missing the transmembrane domain (7). It not only functions as a decoy receptor for IL-13, but also is able to reduce fasting blood glucose, mediated by IL-4 (8). Higher expression of IL-13 RA1 are found in several cancers, often associated with poor prognosis in patients (9-11). Our Avi-tag Biotinylated human IL-13 RA1 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References:

- 1. Aman M.J. et al. (1996) J. Biol. Chem. 271:29265.
- 2. LaPorte S.L. et al. (2008) Cell 132:259.
- 3. Arima K. et al. (2005) J. Biol. Chem. 280:24915.
- 4. Ito T, et al. (2009) J. Biol. Chem. 284:24289.
- 5. Umeshita-Suyama R. et al. (2000) Int. Immunol. 12:1499.
- 6. Roy B, et al. (2002) J. Leukoc. Biol. 72:580.
- 7. Osawa M, et al. (2000) Immunogenetics 51:974.
- 8. Rachmin I, et al. (2017) Am. J. Physiol. Endocrinol. Metab. 313:E663.
- 9. Park M.H. et al. (2017) Ann, Surg. Oncol. 24:3780.
- 10. Cao H, et al. (2016) Oncotarget 7:61183.
- 11. Suzuki A, et al. (2015) Cytokine 75:79.

Rev. 10/27/2020 Page 2 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449